ethyl 4-(4-fluorothiophenyl)-6,7,8-trifluoroquinoline-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 4-(4-fluorothiophenyl)-6,7,8-trifluoroquinoline-3-carboxylate
• 英文别名: ethyl 4-(4-fluorophenylthio)-6,7,8-trifluoroquinoline-3-carboxylate；Ethyl 6,7,8-trifluoro-4-(4-fluorophenyl)sulfanylquinoline-3-carboxylate
• 化学式: C₁₈H₁₁F₄NO₂S
• 分子量: 381.35
• InChiKey: KGWXVQWYZLJWNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  64.5
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 4-(4-fluorothiophenyl)-6,7,8-trifluoroquinoline-3-carboxylate 在 2,2,6,6-四甲基哌啶 、 盐酸 、 正丁基锂 、 水 、 三溴化磷 、 二异丁基氢化铝 、 sodium hydroxide 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 甲苯 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Development of a Practical and Efficient Synthesis of SIPI-4884, a HMG CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia

  摘要：

  An improved process of the novel HMG CoA reductase inhibitor SIPI-4884 has been developed for early preclinical pharmacology and safety studies, and it was made up with an efficient nine-step and scalable process. Significant improvements in the nucleophilic substitution, reduction, Wittig-Horner reaction, and preparation of calcium salt were demonstrated. The overall yield was improved to 17.2%.

  DOI：

  10.1021/op400060z
• 作为产物：
  描述：

  6,7,8-三氟-1,4-二氢-4-氧代-3-喹啉羧酸乙酯 在 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 ethyl 4-(4-fluorothiophenyl)-6,7,8-trifluoroquinoline-3-carboxylate
  参考文献：
  名称：

  Quinoline Compounds, Intermediates, Preparation Methods and Uses Thereof

  摘要：

  一种喹啉类化合物，其化学式为A，药物可接受的溶剂化合物、光学异构体或其多晶形态。公式D的中间体。其中，R1、R2和R3独立地为H、卤素或公式H的取代基，其中，R为H、卤素、C1~C4烷基、C1~C4烷氧基。制备方法及用于制造抑制HMG CoA还原酶和治疗与高血脂相关疾病的药物的用途。与先前公开的氟伐他汀、罗伐他汀、匹伐他汀相比，目前的喹啉类化合物具有更好的抑制HMG CoA还原酶活性。目前的喹啉类化合物可用于治疗与高血脂相关的疾病。

  公开号：

  US20110046379A1

文献信息

• Quinoline Compounds, Intermediates, Preparation Methods and Uses Thereof
  申请人：Cai Zhengyan

  公开号：US20110046379A1

  公开（公告）日：2011-02-24

  A kind of quinoline compounds as formula A, pharmaceutical accepted solvates, optical isomers or polymorphisms thereof. The intermediates of formula D. in which, R 1 , R 2 and R 3 is independently H, halo or the subustitents of formula H, in which, R is H, halo, C 1 ˜C 4 alkyl, C 1 ˜C 4 alkoxyl. The preparation methods and the uses for the manufacture of a medicament of inhibiting the HMG CoA reductase and treating the diseases relating to the high blood fat. Compared with the fluvastatin, rosuvatatin, pitavastatin disclosed in the prior arts, present quinoline compounds have better activity of inhibiting HMG CoA reductase. Present quinoline compounds can be used for treating the diseases relating to the high blood fat.

  一种喹啉类化合物，其化学式为A，药物可接受的溶剂化合物、光学异构体或其多晶形态。公式D的中间体。其中，R1、R2和R3独立地为H、卤素或公式H的取代基，其中，R为H、卤素、C1~C4烷基、C1~C4烷氧基。制备方法及用于制造抑制HMG CoA还原酶和治疗与高血脂相关疾病的药物的用途。与先前公开的氟伐他汀、罗伐他汀、匹伐他汀相比，目前的喹啉类化合物具有更好的抑制HMG CoA还原酶活性。目前的喹啉类化合物可用于治疗与高血脂相关的疾病。
• Synthesis and HMG CoA reductase inhibition of 4-thiophenyl quinolines as potential hypocholesterolemic agents
  作者：Zhengyan Cai、Weicheng Zhou、Lixin Sun

  DOI：10.1016/j.bmc.2007.08.044

  日期：2007.12

  8-trisubstituted-4-chloro-quinoline-3-carboxylates by several reactions and evaluated for their ability to inhibit the rat HMG CoA reductase in vitro. It was found that substitution with a variety of thiophenyl groups at position 4 in quinoline resulted in retention or enhancement of the inhibition and the preferable groups were 4-isopropyl-thiophenyl and 3-methoxy-thiophenyl. (4R,6S)-6-[(E)-2-(6,7,8-trifluoro-4

  由6,7,8-三取代-4-氯喹啉-3-羧酸乙酯经数个反应合成了一系列新颖的基于4-硫代苯基喹啉的甲羟戊酸内酯衍生物，并评估了它们在体外抑制大鼠HMG CoA还原酶的能力。 。发现在喹啉的4位上被各种硫代苯基取代会导致抑制作用的保持或增强，优选的基团是4-异丙基-硫代苯基和3-甲氧基-硫代苯基。（4R，6S）-6-[（E）-2-（6,7,8-三氟-4-异丙基硫代苯基-喹啉-3-基）-乙烯基]-3,4,5,6-四氢-4-羟基-2H-吡喃-2-酮（A16）和（4R，6S）-6-[（E）-2-（6-氟-4,7-二-（3-甲氧基-硫代苯基）-喹啉-3 -基）-乙烯基] -3,4，5，
• Development of a Practical and Efficient Synthesis of SIPI-4884, a HMG CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia
  作者：Qun Hao、Jing Pan、Yongjia Li、Zhengyan Cai、Weicheng Zhou

  DOI：10.1021/op400060z

  日期：2013.6.21

  An improved process of the novel HMG CoA reductase inhibitor SIPI-4884 has been developed for early preclinical pharmacology and safety studies, and it was made up with an efficient nine-step and scalable process. Significant improvements in the nucleophilic substitution, reduction, Wittig-Horner reaction, and preparation of calcium salt were demonstrated. The overall yield was improved to 17.2%.